106 related articles for article (PubMed ID: 12678414)
1. Activities of sitafloxacin (DU-6859a), either singly or in combination with rifampin, against Mycobacterium ulcerans infection in mice.
Dhople AM; Namba K
J Chemother; 2003 Feb; 15(1):47-52. PubMed ID: 12678414
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of sitafloxacin (DU-6859a) alone, or in combination with rifampicin, against Mycobacterium ulcerans.
Dhople AM; Namba K
J Antimicrob Chemother; 2002 Nov; 50(5):727-9. PubMed ID: 12407131
[TBL] [Abstract][Full Text] [Related]
3. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.
Dhople AM; Namba K
Int J Antimicrob Agents; 2003 Mar; 21(3):251-5. PubMed ID: 12636987
[TBL] [Abstract][Full Text] [Related]
4. In vivo susceptibility of Mycobacterium ulcerans to KRM-1648, a new benzoxazinorifamycin, in comparison with rifampicin. Anti-mycobacterial activity of KRM-1648.
Dhople AM
Arzneimittelforschung; 2001; 51(6):501-5. PubMed ID: 11455683
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae.
Dhople AM; Namba K
J Infect Chemother; 2003 Mar; 9(1):12-5. PubMed ID: 12673400
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice.
Dega H; Bentoucha A; Robert J; Jarlier V; Grosset J
Antimicrob Agents Chemother; 2002 Oct; 46(10):3193-6. PubMed ID: 12234844
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of inhibitory effect of rifalazil and rifampicin against Mycobacterium ulcerans infection induced in mice].
Nakanaga K; Saito H; Ishii N; Goto M
Kekkaku; 2004 May; 79(5):333-9. PubMed ID: 15211873
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V
Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546
[TBL] [Abstract][Full Text] [Related]
9. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice.
Bentoucha A; Robert J; Dega H; Lounis N; Jarlier V; Grosset J
Antimicrob Agents Chemother; 2001 Nov; 45(11):3109-12. PubMed ID: 11600364
[TBL] [Abstract][Full Text] [Related]
10. Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin.
Lefrançois S; Robert J; Chauffour A; Ji B; Jarlier V
Antimicrob Agents Chemother; 2007 Feb; 51(2):645-50. PubMed ID: 17101676
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.
Dhople AM
Int J Antimicrob Agents; 2001 Jan; 17(1):57-61. PubMed ID: 11137650
[TBL] [Abstract][Full Text] [Related]
12. Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice.
Marsollier L; Honoré N; Legras P; Manceau AL; Kouakou H; Carbonnelle B; Cole ST
Antimicrob Agents Chemother; 2003 Apr; 47(4):1228-32. PubMed ID: 12654651
[TBL] [Abstract][Full Text] [Related]
13. Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice.
Ji B; Chauffour A; Robert J; Jarlier V
Antimicrob Agents Chemother; 2008 Jun; 52(6):1912-6. PubMed ID: 18391038
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans.
Thangaraj HS; Adjei O; Allen BW; Portaels F; Evans MR; Banerjee DK; Wansbrough-Jones MH
J Antimicrob Chemother; 2000 Feb; 45(2):231-3. PubMed ID: 10660507
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a.
Saito H; Tomioka H; Sato K; Dekio S
Antimicrob Agents Chemother; 1994 Dec; 38(12):2877-82. PubMed ID: 7695276
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
[TBL] [Abstract][Full Text] [Related]
17. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.
Ji B; Chauffour A; Robert J; Lefrançois S; Jarlier V
Antimicrob Agents Chemother; 2007 Oct; 51(10):3737-9. PubMed ID: 17664316
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.
Etuaful S; Carbonnelle B; Grosset J; Lucas S; Horsfield C; Phillips R; Evans M; Ofori-Adjei D; Klustse E; Owusu-Boateng J; Amedofu GK; Awuah P; Ampadu E; Amofah G; Asiedu K; Wansbrough-Jones M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3182-6. PubMed ID: 16048922
[TBL] [Abstract][Full Text] [Related]
19. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
[TBL] [Abstract][Full Text] [Related]
20. Activities of several antimicrobials against Mycobacterium ulcerans infection in mice.
Dega H; Robert J; Bonnafous P; Jarlier V; Grosset J
Antimicrob Agents Chemother; 2000 Sep; 44(9):2367-72. PubMed ID: 10952581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
